Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring A ´ gueda Molinos-Quintana 1 *, Anna Alonso-Saladrigues 2 *, Blanca Herrero 3 , Teresa Caballero-Vela ´zquez 4 , Vı ´ctor Gala ´n-Go ´mez 5 , Melissa Panesso 6 , Montserrat Torrebadell 2 , Javier Delgado-Serrano 4 , Concepcio ´nPe ´rez de Soto 1 , Anna Faura 2 , Berta Gonza ´lez-Martı ´nez 5 , Ana Castillo-Robleda 3 , Cristina Diaz-de-Heredia 6 , Antonio Pe ´rez-Martı ´nez 5 , Jose ´Marı ´aPe ´rez-Hurtado 1 , Susana Rives 7,8 and Jose ´Antonio Pe ´rez-Simo ´n 4 on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC) 1 Pediatric Unit, Department of Hematology, University Hospital Virgen del Rocı ´o, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain, 2 CAR T-cell Unit. Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB). Hospital Sant Joan de De ´u de Barcelona, Barcelona, Spain, 3 Pediatric Hemato-Oncology Department, Peditric University Hospital del Niño Jesu ´s, Madrid, Spain, 4 Department of Hematology, University Hospital Virgen del Rocı ´o, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain, 5 Pediatric Hemato-Oncology Department, University Hospital La Paz, Institute for Health Research (IdiPAZ), Universidad Auto ´noma de Madrid, Madrid, Spain, 6 Division of Pediatric Hematology and Oncology, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain, 7 Pediatric Cancer Center Barcelona (PCCB), Institut de Recerca Sant Joan de De ´u, Leukemia and Pediatric Hematology Disorders, Developmental Tumors Biology Group, Barcelona, Spain, 8 Instituto de Salud Carlos III, Centro de Investigacio ´n Biome ´dica en Red De Enfermedades Raras (CIBERER), Madrid, Spain KEYWORDS B cell aplasia, late B-cell recovery, pre-infusion tumor burden, CD19 CART-cells, relapsed/refractory acute lymphoblastic leukemia, tisagenlecleucel, B-cell monitoring Frontiers in Immunology frontiersin.org01 OPEN ACCESS APPROVED BY Frontiers Editorial Office, Frontiers Media SA, Switzerland *CORRESPONDENCE A ´ gueda Molinos-Quintana [email protected]; [email protected] Anna Alonso-Saladrigues [email protected] RECEIVED 20 January 2024 ACCEPTED 25 January 2024 PUBLISHED 07 February 2024 CITATION Molinos-Quintana A ´ , Alonso-Saladrigues A, Herrero B, Caballero-Vela ´zquez T, Gala ´n-Go ´mez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pe ´rez de Soto C, Faura A, Gonza ´lez-Martı ´nez B, Castillo-Robleda A, Diaz-de-Heredia C, Pe ´rez-Martı ´nez A, Pe ´rez-Hurtado JM, Rives S and Pe ´rez-Simo ´n JA (2024) Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Front. Immunol. 15:1373852. doi: 10.3389/fimmu.2024.1373852 COPYRIGHT © 2024 Molinos-Quintana, Alonso-Saladrigues, Herrero, Caballero-Vela ´zquez, Gala ´n-Go ´mez, Panesso, Torrebadell, Delgado-Serrano, Pe ´rez de Soto, Faura, Gonza ´lez-Martı ´nez, Castillo-Robleda, Diaz-de-Heredia, Pe ´rez-Martı ´nez, Pe ´rez-Hurtado, Rives and Pe ´rez-Simo ´n. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. TYPE Correction PUBLISHED 07 February 2024 DOI 10.3389/fimmu.2024.1373852 A Corrigendum on Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring by Molinos-Quintana A  , Alonso-Saladrigues A, Herrero B, Caballero-Velazquez T, Galan-Gomez V, Panesso M, Torrebadell M, Delgado-Serrano J, Perez de Soto C, Faura A, Gonzalez-Martı  nez B, Castillo-Robleda A, Diaz-de-Heredia C, Perez-Martı  nez A, Perez-Hurtado JM, Rives S and Perez- Simon JA (2024) Front. Immunol. 14:1280580. doi: 10.3389/fimmu.2023.1280580 In the published article, there was an error in the author list, and author “on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)”was erroneously excluded. The corrected author list appears below. A  gueda Molinos-Quintana 1 *, Anna Alonso-Saladrigues 2 *, Blanca Herrero 3 , Teresa Caballero-Velazquez 4 ,Vı ctor Galan- Gomez 5 , Melissa Panesso 6 , Montserrat Torrebadell 2 , Javier Delgado-Serrano 4 , ConcepcionPe rez de Soto 1 , Anna Faura 2 , Berta Gonzalez-Martı nez 5 , Ana Castillo-Robleda 3 ,Cristina Diaz-de-Heredia 6 , Antonio Perez-Martı nez 5 , JoseMarı aPe rez- Hurtado 1 , Susana Rives 7,8 , JoseAntonio Perez-Simon 4 on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC) The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. Publisher’s note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Molinos-Quintana et al. 10.3389/fimmu.2024.1373852 Frontiers in Immunology frontiersin.org02